By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals. With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in automation has never been greater […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!